{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:44:50Z","timestamp":1767725090285,"version":"build-2238731810"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver. QoL questionnaires were collected at baseline, on day 2\/3 after M-PHP, and on day 7 and day 21 after M-PHP, according to study protocol. The results were scored according to EORTC-QLQ C30 global health status (GHS), functional scales, and symptom scales. The difference in scores at baseline and subsequent time points was analyzed with the Wilcoxon signed-rank test and multiple testing Bonferroni correction. Adverse events (AE) were registered up to 30\u00a0days after M-PHP according to CTCAE v5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four patients (14 males; median age 63.0\u00a0years) completed 96 questionnaires. Most scores on all scales declined on day 2\/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores. Three variables were significantly worse on day 21 compared to baseline: fatigue (6\u201333;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), physical functioning (100 vs 86.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), and role functioning (100 vs 66.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Grade 3\/4 AEs consisted mainly of hematological complications, such as leukopenia and thrombopenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>M-PHP causes fatigue and a decline in physical and role functioning in the 1st weeks after treatment, but GHS returns to baseline levels within 21\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence 3<\/jats:title>\n                    <jats:p>Cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-024-03713-0","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:02:12Z","timestamp":1712574132000},"page":"741-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-6858","authenticated-orcid":false,"given":"T. M. L.","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"van Duijn-de Vreugd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lutjeboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M.","family":"Speetjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. G. J.","family":"Tijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Sitsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W. M.","family":"Zoethout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. S. P.","family":"van Rijswijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"van Erkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"6","key":"3713_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","volume":"39","author":"MC Burgmans","year":"2016","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39(6):801\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"3713_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","volume":"40","author":"EM de Leede","year":"2017","unstructured":"de Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J, et al. Prospective clinical and pharmacological evaluation of the delcath system\u2019s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol. 2017;40(8):1196\u2013205.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"3713_CR3","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26. Arch Ophthalmol. 2005;123(12):1639\u201343.","journal-title":"Arch Ophthalmol"},{"issue":"13","key":"3713_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"16","key":"3713_CR5","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","volume":"40","author":"JS Zager","year":"2022","unstructured":"Zager JS, Orloff MM, Ferrucci PF, Glazer ES, Ejaz A, Richtig E, et al. FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A). J Clin Oncol. 2022;40(16):9510.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3713_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309\u201319.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"3713_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/cancers14010118","volume":"14","author":"CLA Dewald","year":"2021","unstructured":"Dewald CLA, Warnke MM, Bruning R, Schneider MA, Wohlmuth P, Hinrichs JB, et al. Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience. Cancers (Basel). 2021;14(1):118.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"3713_CR8","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2021","unstructured":"Meijer TS, Burgmans MC, de Leede EM, de Geus-Oei LF, Boekestijn B, Handgraaf HJM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28(2):1130\u201341.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3713_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","volume":"32","author":"S Modi","year":"2022","unstructured":"Modi S, Gibson T, Vigneswaran G, Patel S, Wheater M, Karydis I, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Res. 2022;32(2):103\u201311.","journal-title":"Melanoma Res"},{"issue":"9","key":"3713_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00270-022-03225-9","volume":"45","author":"TML Tong","year":"2022","unstructured":"Tong TML, Samim M, Kapiteijn E, Meijer TS, Speetjens FM, Bruning R, et al. Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis. Cardiovasc Intervent Radiol. 2022;45(9):1304\u201313.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3713_CR11","doi-asserted-by":"publisher","first-page":"102501","DOI":"10.1016\/j.ctrv.2022.102501","volume":"113","author":"A Vogel","year":"2023","unstructured":"Vogel A, Ochsenreither S, Zager JS, Wacker F, Saborowski A. Chemosaturation for primary and secondary liver malignancies: a comprehensive update of current evidence. Cancer Treat Rev. 2023;113:102501.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3713_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","volume":"143","author":"MM Kirstein","year":"2017","unstructured":"Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol. 2017;143(10):2113\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"3713_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","volume":"42","author":"TS Meijer","year":"2019","unstructured":"Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei LF, Kapiteijn E, de Leede EM, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the delcath systems\u2019 second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42(6):841\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"3713_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","volume":"40","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, Koch SA, Lotz G, Gebauer B, Willinek W, Engelke C, et al. Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol. 2017;40(6):864\u201372.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3713_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000947","author":"G Vigneswaran","year":"2023","unstructured":"Vigneswaran G, Malalasekera W, Smith V, Gibson T, Patel S, Wheater M, et al. Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma. Melanoma Res. 2023. https:\/\/doi.org\/10.1097\/CMR.0000000000000947.","journal-title":"Melanoma Res"},{"issue":"15","key":"3713_CR16","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23(15):3465\u201374.","journal-title":"J Clin Oncol"},{"key":"3713_CR17","doi-asserted-by":"publisher","DOI":"10.3791\/53795-v","author":"EM de Leede","year":"2016","unstructured":"de Leede EM, Burgmans MC, Martini CH, Tijl FG, van Erkel AR, Vuyk J, et al. Percutaneous hepatic perfusion (PHP) with melphalan as a treatment for unresectable metastases confined to the liver. J Vis Exp. 2016. https:\/\/doi.org\/10.3791\/53795-v.","journal-title":"J Vis Exp"},{"key":"3713_CR18","doi-asserted-by":"publisher","DOI":"10.1055\/a-1348-1932","author":"CLA Dewald","year":"2021","unstructured":"Dewald CLA, Hinrichs JB, Becker LS, Maschke S, Meine TC, Saborowski A, et al. Chemosaturation with percutaneous hepatic perfusion: outcome and safety in patients with metastasized uveal melanoma. Rofo. 2021. https:\/\/doi.org\/10.1055\/a-1348-1932.","journal-title":"Rofo"},{"key":"3713_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3713_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/CMR.0000000000000286","volume":"26","author":"EM de Leede","year":"2016","unstructured":"de Leede EM, Burgmans MC, Kapiteijn E, Luyten GP, Jager MJ, Tijl FG, et al. Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. Melanoma Res. 2016;26(6):588\u201394.","journal-title":"Melanoma Res"},{"key":"3713_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01705","author":"R Olofsson Bagge","year":"2023","unstructured":"Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, et al. Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, Open-label, phase III trial (the SCANDIUM Trial). J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.22.01705.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3713_CR22","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.3390\/cancers13184726","volume":"13","author":"MS Bethlehem","year":"2021","unstructured":"Bethlehem MS, Katsarelias D, Olofsson BR. Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases. Cancers (Basel). 2021;13(18):4726.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3713_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00270-020-02643-x","volume":"44","author":"R Loffroy","year":"2021","unstructured":"Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, et al. Short-term safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-centre analysis of 200 patients in France. Cardiovasc Intervent Radiol. 2021;44(1):36\u201349.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3713_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.1007\/s00270-024-03733-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000}}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03713-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:04:14Z","timestamp":1718017454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03713-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03713-0","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00270-024-03733-w","URL":"https:\/\/doi.org\/10.1007\/s00270-024-03733-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MB has received consultancy fees from Delcath Systems. EK has consultancy\/advisory relationships with Bristol Myers Squibb, Novartis, Pierre Fabre, Immunocore, and Lilly and received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis, and Pierre-Fabre. Not related to current work and paid to institute. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}